Status:
COMPLETED
Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal
Lead Sponsor:
Biomedical Research Center EPLS
Collaborating Sponsors:
Biofabri, S.L
TuBerculosis Vaccine Initiative
Conditions:
Tuberculosis
Eligibility:
All Genders
11-12 years
Brief Summary
A cross-sectional childhood M. tuberculosis infection survey of age-specific rates (defined by positivity to the test QuantiFERON-TB Gold Plus) will be conducted in Senegal to collect information on t...
Detailed Description
MTBVAC is a new TB vaccine candidate based on an attenuated clinical isolate of M. tuberculosis. The clinical development consortium of this EDCTP program is preparing for future years an MTBVAC effic...
Eligibility Criteria
Inclusion
- Children resident in the study area (St Louis City)
- Obtaining written consent from one of the parents / guardians.
- Children meeting one the following age criterion:
- 1-year old child (12 months -1/+4 months);
- 2-year-old child (24 months -1/+4 months);
- 5-year old child (60 months +/-6 months);
- 12-year old child (12 years old +/-6 months);
Exclusion
- Child resident outside the study area.
- Participation refusal by one of the parents / guardians.
- Objection of the child belonging to the 12-year old group.
- Child with a known chronic pathology (severe asthma, epilepsy, type 1 diabetes, severe immunosuppression ...)
- Child considered by the Principal Investigator as medically unfit to participate in the study.
Key Trial Info
Start Date :
July 27 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 27 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03767946
Start Date
July 27 2018
End Date
July 27 2022
Last Update
July 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomedical Research Center EPLS
Saint-Louis, France, BP226